Online Enquiry
Subscribe
Log in / New User
Retrieve Password
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Log In
|
New User Registration
|
Retrieve Password
Log In
News
TheMarket
IndustryNews
RegulatoryNews
GeneralHealth
Legal/IPRNews
Product/R&DNews
API/BulkDrugNews
PeopleintheNews
OtherNews
TopNewsWorldwide
FEATURE ARTICLES
Editorials
FocusArticles
ExpertOpinions
Interviews
CaseStudies
CompanyProfiles
NewsinFocus
Editor'sPicks
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
NHSA Seeks Public Input on 2025 Drug Reimbursement and Innovation List Reform ...
The NHSA has released for public consultation a set of draft policy documents outlining the 2025 adjustment framework for the NRDL and a separate list for commercial heal...
(7/1/2025)
Accelerating US Oncology Drug Development Usin... (7/23/2025)
PharmaDJ's China Biopharma Tracker – June 202... (7/22/2025)
Analysing Key Trends In China's Patent-linkage... (7/12/2025)
China's Rising Biotechnology Sector: Friend or... (7/10/2025)
As Chinese-developed Drugs Draw U.S. Interest,... (7/8/2025)
FDA's Crackdown and China's Dealmaking: Warnin... (7/2/2025)
Medical Advances Soar With APAC's Clinical Tri... (7/2/2025)
Tracking the Crossroads of Policy, Innovation,... (7/1/2025)
BeOne Launches Phase III Trial Comparing Subcu... (7/1/2025)
China Launches Landmark Measures to Boost Inno... (7/1/2025)
Analyzing Key Trends in China's Patent-Linkage... (6/27/2025)
Fresh Antitrust Guidelines to Address Pharmace... (6/27/2025)
Recent Official and Executive Moves (7/26/2025)
China's Basic Medical Insurance Fund Rep... (7/26/2025)
Ambroxol Hydrochloride Drops Reclassifie... (7/26/2025)
Newish Secures Series B1 Investment to ... (7/25/2025)
Yangtze River Pharma's Tunodafil Wins NM... (7/25/2025)
Eisai's Lenvatinib Secures NMPA Approval... (7/25/2025)
AusperBio Advances AHB‑137 to Phase 3 A... (7/25/2025)
Everest Secures $200M in Share Placement... (7/25/2025)
China Launches Nationwide Pilot Program ... (7/25/2025)
Roche Sees Strong China Pharma Growth in... (7/24/2025)
Pfizer Finalizes 3SBio Deal, Prepares Gl... (7/24/2025)
Kelun-Biotech Initiates Phase I Trial of... (7/24/2025)
Cascade Pharma's CS0159 Wins FDA Breakth... (7/24/2025)
Zonsen PepLib Biotech Closes ~CNY 100M S... (7/24/2025)
China-Singapore Nanovaccine Prevents Can... (7/23/2025)
SAMR Orders Simcere to Reverse Unnotifie... (7/23/2025)
DualityBio's DB‑1310 Earns FDA Fast‑Tr... (7/23/2025)
Qilu Initiates Global Phase III Trial of... (7/23/2025)
China Hospitals Prioritize Local Innovation, Digital He...
China's Pharma Market Faces Mixed Performance in Q1 202...
China's Retail Pharmacy Market Hits CNY 941.1B in 2024 ...
NH's DB6: China's Consumer Healthcare Market Underperfo...
China's Hospital Drug Market Shows Slight Growth in 202...
Everest Secures $200M in Share Placement while Epirium ...
Eisai's Lenvatinib Secures NMPA Approval in China
Newish Secures Series B1 Investment to Propel Nucleic ...
Zonsen PepLib Biotech Closes ~CNY 100M Series B Round
Pfizer Finalizes 3SBio Deal, Prepares Global Phase 3 La...
Ambroxol Hydrochloride Drops Reclassified as OTC Drug i...
CDE Issues Q&A Guidance on Pharmaceutical Similarity St...
CDE Solicits Comments on Proposed Labeling Update for P...
China Issues New Draft Guidelines for Pharmaceutical De...
China Unveils New Clinical Trial Guidelines for Antibac...
China's Basic Medical Insurance Fund Reports Surplus in...
China Launches Nationwide Pilot Program for Smart Medic...
China Launches 11th Round of VBP, Covering 55 Medicines...
China Releases 2nd Batch of Clinical Guidelines for Rar...
China 2024 Healthcare Insurance Report: Milestones in C...
SAMR Orders Simcere to Reverse Unnotified Merger Over C...
U.S. Lawmakers Raise Fresh Alarm Over GenScript's China...
Record China Pharma Monopoly Fine Sends Strong Deterren...
Conjupro Files USPTO Challenge on Ascletis' U.S. Patent...
China's Draft National Medical Security Law: Seven Key ...
China Struggles to Maintain Grip on India's Bulk Drug M...
API China 2025 Ends with High Attendance and Global Ind...
FDA Issues Warning Letters to Two Chinese API Manufactu...
Implications of China's Growing Influence in Global Pha...
FDA Issues Warning to Tianjin Darentang for Manufacturi...
AusperBio Advances AHB‑137 to Phase 3 After Green Ligh...
Yangtze River Pharma's Tunodafil Wins NMPA Nod
Cascade Pharma's CS0159 Wins FDA Breakthrough For PBC
Kelun-Biotech Initiates Phase I Trial of SKB107
Kelun‑Biotech Launches Phase I Trial of SKB107 in Chin...
BioAtla and BeiGene Revise Global Deal for Novel Condit...
Pfizer to Absorb Mylan, Creating Global Generic Powerho...
PhRMA Calls for Trade Deals That Force Countries to Pay...
IQVIA: Global Pharma to Grow Slower in the Next Five Ye...
Pfizer and GSK Announce JV to Create a Global Consumer ...
Recent Official and Executive Moves
Recent Executive Moves
Astellas Pharma Executive Sentenced to 3½ Years in Chi...
Recent Official and Executive Moves
Recent Official and Executive Moves
China Introduces Plan for Pudong New Area's Pilot Compr...
Upcoming Event: 2023 Pharma CI USA Conference & Exhibit...
Upcoming Event: 15th Annual Pharma Market Research Conf...
Upcoming Event: 6th International Conference on Emergin...
Upcoming Event: PHARM Connect Congress
Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...
WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...
2023 Order Form + Product Descripti...
WiCON Publishes the China Pharmaceu...
WiCON Publishes the China Pharmaceu...
WiCON Publishes the China Pharmaceu...
WiCON Publishes the China Pharmaceu...
WEEKLY e-ALERT(Premium)
WEEKLY e-ALERT(Basic)
GENERAL INFORMATION
TERMS/CONDITIONS OF USE
PRIVACY STATEMENT
JOIN THE MAILING LIST
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit